Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Xiaojuan Chen, BsN, MsN, Foong-Gwan Lee, BsN, Shi Hui Clarice Choong, MBBS, MRCP, Xiao-Shi Saw, BSc(Pharm), Lon-Wann Sai, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Hian Li Esther Hian Li Chan, MBBS, MRCP, FRCPATH, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Yen Lin Chee, MBBS, FRCPATH, PhD, Yee Mei Lee, BsN, MsN, PhD

Blood (2019) 134 (Supplement_1): 2152.

https://doi.org/10.1182/blood-2019-129858

Published: 2019

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Vittorio Ruggero Zilioli, Periana Minga, Lara Crucitti, Erika Meli, Monica Luigia Torretta, Anna Esposito, Chiara Rusconi, Roberto Cairoli

Blood (2018) 132 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2018-99-116543

Published: 2018

Journal Articles

Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan

Tomiteru Togano, MD PhD, Yuhko Suzuki, MD PhD, William Tse, MD, Hikaru Kume, PharmD, PhD

Blood (2018) 132 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2018-99-110546

Published: 2018

Journal Articles

Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Malignancy Patients Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC)

Lee S. Schwartzberg, MD FACP, Eric J. Roeland, MD, Paul J.E. Miller, PhD, Mark S. Walker, PhD

Blood (2016) 128 (22): 2410.

https://doi.org/10.1182/blood.V128.22.2410.2410

Published: 2016

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

Journal Articles

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Talha Badar, MBBS, FCPS, Gloria Mattiuzzi, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Guillermo Garcia Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3887.

https://doi.org/10.1182/blood.V122.21.3887.3887

Published: 2013

Journal Articles

A Phase II Study Of Aprepitant As Anti-Emetic Prophylaxis In Patients Receiving Induction Chemotherapy For AML

Joseph Brandwein, MD, FRCPC, Karen W.L. WL Yee, MD, Andre C Schuh, MD, Vikas Gupta, MD, FRCP, FRCPath, Jack T Seki, PharmD

Blood (2013) 122 (21): 5035.

https://doi.org/10.1182/blood.V122.21.5035.5035

Published: 2013

Journal Articles

A Randomized Controlled Study Evaluating The Efficacy Of Aprepitant For Highly Emetogenic Chemotherapies In Hematological Malignancies

Ryo Nasu, Dr, Yasuhito Nannya, MD, PhD, Akihide Yoshimi, MD, PhD, Masataka Hosoi, M.D., Ph.D., Kouki Ueda, MD, PhD, Yumiko Yoshiki, MD, PhD, Shunya Arai, MD, PhD, Akihito Shinohara, M.D., Ph.D., Fumihiko Nakamura, MD, PhD, Mineo Kurokawa, MD, PhD

Blood (2013) 122 (21): 1790.

https://doi.org/10.1182/blood.V122.21.1790.1790

Published: 2013

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Andrew M. Evens, DO, MSc, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD, FACP, Irene Helenowski, MS, Justin Kline, MD, Annette Larsen, B.A., R.N., Jane N. Winter, M.D., Sonali M. Smith, MD, Koen M. Van Besien, MD

Blood (2011) 118 (21): 1646.

https://doi.org/10.1182/blood.V118.21.1646.1646

Published: 2011

Journal Articles

Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells

Eric Haarman, MD, PhD, Jacqueline Cloos, PhD, Christian M. Zwaan, MD, PhD, Valerie de Haas, MD, PhD, Dirk Reinhardt, MD, PhD, Ursula Creutzig, MD, PhD, Gertjan J. Kaspers, MD, PhD

Blood (2011) 118 (21): 4873.

https://doi.org/10.1182/blood.V118.21.4873.4873

Published: 2011

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

Likelihood of a Subsequent Chemotherapy Induced Nausea and Vomiting Event In Patients with Hematologic Malignancies Receiving Chemotherapy.

Bruce Feinberg, DO, Lee S. Schwartzberg, MD, FACP, James Gilmore, PharmD, Sally Haislip, RPh, James Jackson, PharmD, MPH, Gagan Jain, PhD, Sanjeev Balu, PhD, MBA, Deborah Buchner, PhD

Blood (2010) 116 (21): 3819.

https://doi.org/10.1182/blood.V116.21.3819.3819

Published: 2010

Journal Articles

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Delva Deauna-Limayo, MD, Omar Aljitawi, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Jo Wick, Joseph McGuirk, DO

Blood (2010) 116 (21): 1335.

https://doi.org/10.1182/blood.V116.21.1335.1335

Published: 2010

Journal Articles

Palonosetron Versus Other 5-HT 3 -Receptor Antagonists for the Prevention of Chemotherapy Induced Nausea and Vomiting In Patients with Hematologic Malignancies Treated In A Hospital Outpatient Setting

Chris Craver, MA, Julie Gayle, MPH, Sanjeev Balu, PhD, MBA, Deborah Buchner, PhD

Blood (2010) 116 (21): 2567.

https://doi.org/10.1182/blood.V116.21.2567.2567

Published: 2010

Journal Articles

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Patrick Stiff, MD, Mary Fox-Geiman, PharmD, Karen Kiley, MSN, NP, Nancy Porter, MSN, APN, Karen Rychlik, BA, Donna Fletcher-Gonzalez, PharmD, Amir Toor, MD, Scott E. Smith, MD, PhD, Tulio Rodriguez, MD

Blood (2009) 114 (22): 2267.

https://doi.org/10.1182/blood.V114.22.2267.2267

Published: 2009

Journal Articles

Prognostic Analysis of Hodgkin Lymphoma (HL) in JAPAN

Blood (2008) 112 (11): 4830.

https://doi.org/10.1182/blood.V112.11.4830.4830

Published: 2008

NARROW

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan

Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Malignancy Patients Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC)

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

A Phase II Study Of Aprepitant As Anti-Emetic Prophylaxis In Patients Receiving Induction Chemotherapy For AML

A Randomized Controlled Study Evaluating The Efficacy Of Aprepitant For Highly Emetogenic Chemotherapies In Hematological Malignancies

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

Likelihood of a Subsequent Chemotherapy Induced Nausea and Vomiting Event In Patients with Hematologic Malignancies Receiving Chemotherapy.

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Palonosetron Versus Other 5-HT 3 -Receptor Antagonists for the Prevention of Chemotherapy Induced Nausea and Vomiting In Patients with Hematologic Malignancies Treated In A Hospital Outpatient Setting

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Prognostic Analysis of Hodgkin Lymphoma (HL) in JAPAN

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only